| First Author | Kölle J | Year | 2022 |
| Journal | iScience | Volume | 25 |
| Issue | 6 | Pages | 104440 |
| PubMed ID | 35707726 | Mgi Jnum | J:326091 |
| Mgi Id | MGI:7293905 | Doi | 10.1016/j.isci.2022.104440 |
| Citation | Kolle J, et al. (2022) Targeted deletion of Interleukin-3 results in asthma exacerbations. iScience 25(6):104440 |
| abstractText | The cytokine interleukin-3 (IL-3) acts on early hematopoietic precursor cells. In humans, Treg cells secrete IL-3 and repress inflammatory cells except for basophils. The present study aims to elucidate the contribution of IL-3 in the development and the course of allergic asthma. We therefore analyzed the secretion of IL-3 in PBMCs and total blood cells in two cohorts of pre-school children with and without asthma. In a murine model of allergic asthma, we analyzed the phenotype of IL-3(-/-) mice compared to wild-type mice. PBMCs from asthmatic children showed increased IL-3 secretion, which directly correlated with improved lung function. IL-3(-/-) asthmatic mice showed increased asthmatic traits. Moreover, IL-3-deficient mice had a defect in T regulatory cells in the lung. In conclusion, IL-3 downregulation was found associated with more severe allergic asthma in pre-school children. Consistently, targeting IL-3 resulted in an induced pathophysiological response in a murine model of allergic asthma. |
